Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Period	Debt/Equity
2015-12-31	0.14
2016-12-31	0.54
2017-12-31	0.28
2018-12-31	1.90
2019-12-31	1.84
2020-12-31	1.89
2021-12-31	2.03
2022-12-31	17.83
2023-12-31	-5.01
2024-12-31	6.10

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INSM	$160.18	+0.00%	3.36M
3
4
5

Insmed Incorporated (INSM) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Insmed Incorporated Data in Excel

More INSM Financial Data